4.7 Review

Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment

期刊

ANNALS OF ONCOLOGY
卷 22, 期 12, 页码 2546-2555

出版社

OXFORD UNIV PRESS
DOI: 10.1093/annonc/mdr017

关键词

aromatase inhibitor; bisphosphonate; bone loss; breast cancer; fracture risk; zoledronic acid

类别

资金

  1. Novartis Pharmaceuticals Corporation
  2. Amgen
  3. AstraZeneca
  4. Eli Lilly
  5. GlaxoSmithKline
  6. Novartis
  7. Pfizer
  8. Roche
  9. Sanofi-Aventis
  10. Wyeth
  11. Schering
  12. Monogram Biosciences
  13. Oncogene Science
  14. PA Breast Cancer Coalition

向作者/读者索取更多资源

Background: Bone mineral density (BMD)-based guidelines for bone-directed therapy in women with early breast cancer (EBC) appear inadequate for averting fractures, particularly during aromatase inhibitor (AI) therapy. Therefore, an algorithm was developed to better assess risk and direct treatment (Hadji P, Body JJ, Aapro MS et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 2008; 19: 1407-1416). Here, we provide updated guidance on pharmacologic interventions to prevent/treat aromatase inhibitor-associated bone loss (AIBL). Design: Systematic literature review identified recent advances in preventing/treating AIBL. Individual agents were assessed based on trial size, design, follow-up, and safety. Results: Fracture risk factors in patients with EBC remain unchanged (Hadji P, Body JJ, Aapro MS et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 2008; 19: 1407-1416). The World Health Organization Fracture Risk Assessment Tool algorithm includes fracture risk factors plus BMD but does not adequately address AIBL effects. Several antiresorptives can prevent/treat AIBL. However, concerns regarding compliance and long-term efficacy/safety remain. Overall, evidence is strongest for twice-yearly zoledronic acid (ZOL), and recent advances support additional anticancer benefits from ZOL. Conclusions: All patients initiating AIs need advice regarding exercise, calcium/vitamin D supplements, baseline BMD monitoring (when available), and bone-directed therapy if T-score < - 22.0 or at least two fracture risk factors were observed. Patients with T-score > - 22.0 and no risk factors should be managed based on BMD loss during years 1-2. Unsatisfactory compliance/decreasing BMD after 12-24 months on oral bisphosphonates should trigger a switch to i.v. bisphosphonate.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据